Interferon-α-2b and ribavirin for retreatment of chronic hepatitis C

Robert M. Dettmer, John F. Reinus, David J. Clain, Ayse Aytaman, Hulya Levendoglu, Alan A. Bloom, Mary P. Isaacson, Mitchel Spinnell, Douglas Meyer, Viyada Sarabanchong, Yatian Zhang, Reuben J. Garcia-Carrasquillo, David D. Markowitz, Arthur M. Magun, Howard J. Worman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Aims: Subjects with chronic hepatitis C who fail treatment with interferon-α are generally divided into two groups: "relapsers" who normalized serum aminotransferase activity and have undetectable viral RNA during treatment and "non-responders" who do not achieve these results. The aim of this study was to examine retreatment of such subjects. Methodology: We studied 117 subjects with chronic hepatitis C who failed treatment with interferon-α, 87 of whom were "non-responders" and 30 "relapsers." Retreatment was with either interferon-α-2b plus ribavirin for 48 weeks or with interferon-α-2b plus placebo for 24 weeks followed by 24 weeks of combined therapy. Results: Sustained response rates, defined as undetectable viral RNA in serum 6 months after retreatment, were 53% in "relapsers" and 10% in "non-responders" (P<0.005). There was no significant difference if ribavirin was given for 24 or 48 weeks. In "non-responders" infected with genotypes other than type 1, 42% achieved a sustained response compared to 5% infected with genotype 1 (P=0.027; odds ratio 7.09). Conclusions: Treatment with interferon-α-2b plus ribavirin is effective in approximately 50% of "relapsers" and "non-responders" infected with non-type 1 genotypes of hepatitis C virus. Thais therapy is only marginally effective in "non-responders" infected with genotype 1a or 1b.

Original languageEnglish (US)
Pages (from-to)758-763
Number of pages6
JournalHepato-Gastroenterology
Volume49
Issue number45
StatePublished - 2002
Externally publishedYes

Fingerprint

Retreatment
Ribavirin
Chronic Hepatitis C
Interferons
Genotype
Viral RNA
Therapeutics
Transaminases
Serum
Hepacivirus
Odds Ratio
Placebos

Keywords

  • Cirrhosis
  • Hepatitis C
  • Interferon-alpha
  • Liver
  • Ribavirin
  • Viral hepatitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Dettmer, R. M., Reinus, J. F., Clain, D. J., Aytaman, A., Levendoglu, H., Bloom, A. A., ... Worman, H. J. (2002). Interferon-α-2b and ribavirin for retreatment of chronic hepatitis C. Hepato-Gastroenterology, 49(45), 758-763.

Interferon-α-2b and ribavirin for retreatment of chronic hepatitis C. / Dettmer, Robert M.; Reinus, John F.; Clain, David J.; Aytaman, Ayse; Levendoglu, Hulya; Bloom, Alan A.; Isaacson, Mary P.; Spinnell, Mitchel; Meyer, Douglas; Sarabanchong, Viyada; Zhang, Yatian; Garcia-Carrasquillo, Reuben J.; Markowitz, David D.; Magun, Arthur M.; Worman, Howard J.

In: Hepato-Gastroenterology, Vol. 49, No. 45, 2002, p. 758-763.

Research output: Contribution to journalArticle

Dettmer, RM, Reinus, JF, Clain, DJ, Aytaman, A, Levendoglu, H, Bloom, AA, Isaacson, MP, Spinnell, M, Meyer, D, Sarabanchong, V, Zhang, Y, Garcia-Carrasquillo, RJ, Markowitz, DD, Magun, AM & Worman, HJ 2002, 'Interferon-α-2b and ribavirin for retreatment of chronic hepatitis C', Hepato-Gastroenterology, vol. 49, no. 45, pp. 758-763.
Dettmer RM, Reinus JF, Clain DJ, Aytaman A, Levendoglu H, Bloom AA et al. Interferon-α-2b and ribavirin for retreatment of chronic hepatitis C. Hepato-Gastroenterology. 2002;49(45):758-763.
Dettmer, Robert M. ; Reinus, John F. ; Clain, David J. ; Aytaman, Ayse ; Levendoglu, Hulya ; Bloom, Alan A. ; Isaacson, Mary P. ; Spinnell, Mitchel ; Meyer, Douglas ; Sarabanchong, Viyada ; Zhang, Yatian ; Garcia-Carrasquillo, Reuben J. ; Markowitz, David D. ; Magun, Arthur M. ; Worman, Howard J. / Interferon-α-2b and ribavirin for retreatment of chronic hepatitis C. In: Hepato-Gastroenterology. 2002 ; Vol. 49, No. 45. pp. 758-763.
@article{25ca80e3a7df4204aa299011e9684d25,
title = "Interferon-α-2b and ribavirin for retreatment of chronic hepatitis C",
abstract = "Background/Aims: Subjects with chronic hepatitis C who fail treatment with interferon-α are generally divided into two groups: {"}relapsers{"} who normalized serum aminotransferase activity and have undetectable viral RNA during treatment and {"}non-responders{"} who do not achieve these results. The aim of this study was to examine retreatment of such subjects. Methodology: We studied 117 subjects with chronic hepatitis C who failed treatment with interferon-α, 87 of whom were {"}non-responders{"} and 30 {"}relapsers.{"} Retreatment was with either interferon-α-2b plus ribavirin for 48 weeks or with interferon-α-2b plus placebo for 24 weeks followed by 24 weeks of combined therapy. Results: Sustained response rates, defined as undetectable viral RNA in serum 6 months after retreatment, were 53{\%} in {"}relapsers{"} and 10{\%} in {"}non-responders{"} (P<0.005). There was no significant difference if ribavirin was given for 24 or 48 weeks. In {"}non-responders{"} infected with genotypes other than type 1, 42{\%} achieved a sustained response compared to 5{\%} infected with genotype 1 (P=0.027; odds ratio 7.09). Conclusions: Treatment with interferon-α-2b plus ribavirin is effective in approximately 50{\%} of {"}relapsers{"} and {"}non-responders{"} infected with non-type 1 genotypes of hepatitis C virus. Thais therapy is only marginally effective in {"}non-responders{"} infected with genotype 1a or 1b.",
keywords = "Cirrhosis, Hepatitis C, Interferon-alpha, Liver, Ribavirin, Viral hepatitis",
author = "Dettmer, {Robert M.} and Reinus, {John F.} and Clain, {David J.} and Ayse Aytaman and Hulya Levendoglu and Bloom, {Alan A.} and Isaacson, {Mary P.} and Mitchel Spinnell and Douglas Meyer and Viyada Sarabanchong and Yatian Zhang and Garcia-Carrasquillo, {Reuben J.} and Markowitz, {David D.} and Magun, {Arthur M.} and Worman, {Howard J.}",
year = "2002",
language = "English (US)",
volume = "49",
pages = "758--763",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "45",

}

TY - JOUR

T1 - Interferon-α-2b and ribavirin for retreatment of chronic hepatitis C

AU - Dettmer, Robert M.

AU - Reinus, John F.

AU - Clain, David J.

AU - Aytaman, Ayse

AU - Levendoglu, Hulya

AU - Bloom, Alan A.

AU - Isaacson, Mary P.

AU - Spinnell, Mitchel

AU - Meyer, Douglas

AU - Sarabanchong, Viyada

AU - Zhang, Yatian

AU - Garcia-Carrasquillo, Reuben J.

AU - Markowitz, David D.

AU - Magun, Arthur M.

AU - Worman, Howard J.

PY - 2002

Y1 - 2002

N2 - Background/Aims: Subjects with chronic hepatitis C who fail treatment with interferon-α are generally divided into two groups: "relapsers" who normalized serum aminotransferase activity and have undetectable viral RNA during treatment and "non-responders" who do not achieve these results. The aim of this study was to examine retreatment of such subjects. Methodology: We studied 117 subjects with chronic hepatitis C who failed treatment with interferon-α, 87 of whom were "non-responders" and 30 "relapsers." Retreatment was with either interferon-α-2b plus ribavirin for 48 weeks or with interferon-α-2b plus placebo for 24 weeks followed by 24 weeks of combined therapy. Results: Sustained response rates, defined as undetectable viral RNA in serum 6 months after retreatment, were 53% in "relapsers" and 10% in "non-responders" (P<0.005). There was no significant difference if ribavirin was given for 24 or 48 weeks. In "non-responders" infected with genotypes other than type 1, 42% achieved a sustained response compared to 5% infected with genotype 1 (P=0.027; odds ratio 7.09). Conclusions: Treatment with interferon-α-2b plus ribavirin is effective in approximately 50% of "relapsers" and "non-responders" infected with non-type 1 genotypes of hepatitis C virus. Thais therapy is only marginally effective in "non-responders" infected with genotype 1a or 1b.

AB - Background/Aims: Subjects with chronic hepatitis C who fail treatment with interferon-α are generally divided into two groups: "relapsers" who normalized serum aminotransferase activity and have undetectable viral RNA during treatment and "non-responders" who do not achieve these results. The aim of this study was to examine retreatment of such subjects. Methodology: We studied 117 subjects with chronic hepatitis C who failed treatment with interferon-α, 87 of whom were "non-responders" and 30 "relapsers." Retreatment was with either interferon-α-2b plus ribavirin for 48 weeks or with interferon-α-2b plus placebo for 24 weeks followed by 24 weeks of combined therapy. Results: Sustained response rates, defined as undetectable viral RNA in serum 6 months after retreatment, were 53% in "relapsers" and 10% in "non-responders" (P<0.005). There was no significant difference if ribavirin was given for 24 or 48 weeks. In "non-responders" infected with genotypes other than type 1, 42% achieved a sustained response compared to 5% infected with genotype 1 (P=0.027; odds ratio 7.09). Conclusions: Treatment with interferon-α-2b plus ribavirin is effective in approximately 50% of "relapsers" and "non-responders" infected with non-type 1 genotypes of hepatitis C virus. Thais therapy is only marginally effective in "non-responders" infected with genotype 1a or 1b.

KW - Cirrhosis

KW - Hepatitis C

KW - Interferon-alpha

KW - Liver

KW - Ribavirin

KW - Viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=0036016764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036016764&partnerID=8YFLogxK

M3 - Article

C2 - 12063985

AN - SCOPUS:0036016764

VL - 49

SP - 758

EP - 763

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 45

ER -